北京阳光诺和药物研究股份有限公司 关于注销孙公司南京诺和欣医药科技有限公司暨关联交易的进展公告

Core Points - The company has completed the deregistration of its subsidiary, Nanjing Nuohua Pharmaceutical Technology Co., Ltd. (Nuohua), as approved by the board on May 12, 2025 [1][2] - The deregistration process was finalized after receiving the registration notice from the Nanjing Jiangbei New District Administrative Approval Bureau [1] - The deregistration will not have a significant impact on the company's overall business development and profitability [2] Summary by Sections - Deregistration Process - The board of directors approved the deregistration of Nuohua on May 12, 2025 [1] - The company received the registration notice confirming the completion of the deregistration [1] - Impact on Financials - The consolidation scope of the company's financial statements will change, but it will not significantly affect the overall financial statements [2] - There are no adverse effects on the interests of the company and all shareholders, particularly minority shareholders [2]